

Dwight H Owen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5553365/publications.pdf>

Version: 2024-02-01

82
papers

2,255
citations

331670

21
h-index

254184

43
g-index

84
all docs

84
docs citations

84
times ranked

3231
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1157-1165.	4.2	12
2	Association between immune-related adverse event timing and treatment outcomes. <i>Oncolmmunology</i> , 2022, 11, 2017162.	4.6	33
3	Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, 345-355.	2.6	13
4	Neuroendocrine and Rare Tumor Advances: A New and Promising TRAIL Emerges. <i>Clinical Cancer Research</i> , 2022, 28, 1748-1750.	7.0	3
5	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	2.4	6
6	Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. <i>Clinical Lung Cancer</i> , 2021, 22, e487-e497.	2.6	6
7	Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid. <i>Clinical Lung Cancer</i> , 2021, 22, e442-e445.	2.6	4
8	Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2761-2769.	4.2	7
9	Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans. <i>JCSM Rapid Communications</i> , 2021, 4, 232-244.	1.6	6
10	Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4160-4167.	7.0	64
11	Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 813-819.	1.0	23
12	Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. <i>Clinical Lung Cancer</i> , 2021, 22, e519-e527.	2.6	7
13	Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 915-921.	4.9	27
14	Targeting Tumor-Associated Macrophages in Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5318.	3.7	26
15	Acute kidney injury in patients treated with immune checkpoint inhibitors. , 2021, 9, e003467.		103
16	Harmonized Outcome Measures for Use in Non-Small Cell Lung Cancer Patient Registries and Clinical Practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , .	4.9	0
17	Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1856.	7.1	74
18	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	1.6	135

#	ARTICLE	IF	CITATIONS
19	<p>>Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers</p><p></p>. Cancer Management and Research, 2020, Volume 12, 11743-11749.	1.9	5
20	Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia, 2020, 34, 3197-3205.	7.2	45
21	Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunology, Immunotherapy, 2020, 69, 2403-2408.	4.2	10
22	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 1952.	7.1	241
23	Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications. BMC Cancer, 2020, 20, 383.	2.6	45
24	The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer. Current Oncology Reports, 2020, 22, 54.	4.0	20
25	Biomarkers for Immunotherapy. Thoracic Surgery Clinics, 2020, 30, 207-214.	1.0	4
26	Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. Cancer, 2020, 126, 3689-3697.	4.1	11
27	Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-“Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations. Clinical Lung Cancer, 2020, 21, e265-e269.	2.6	7
28	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunology, Immunotherapy, 2020, 69, 1177-1187.	4.2	66
29	Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy. Clinical Lung Cancer, 2020, 21, e243-e245.	2.6	2
30	Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics. Histopathology, 2020, 77, 240-249.	2.9	13
31	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177.		1
32	CLO20-054: A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, CLO20-054.	4.9	9
33	Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1287-1290.	4.9	5
34	Abstract 4394: Utilizing pharmacokinetics and toxicity data in the translational drug interaction knowledgebase to bridge the phase I cancer drug combination studies. , 2020, , .		0
35	Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2541-2546.	2.5	93
36	Reply to J. Delyon et al. Journal of Clinical Oncology, 2019, 37, 3564-3565.	1.6	0

#	ARTICLE	IF	CITATIONS
37	SECOND CANCER INCIDENCE IN CLL PATIENTS RECEIVING BTK INHIBITORS. Hematological Oncology, 2019, 37, 382-383.	1.7	0
38	Metastatic Adrenocortical Carcinoma: a Single Institutional Experience. Hormones and Cancer, 2019, 10, 161-167.	4.9	13
39	DLL3: an emerging target in small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 61.	17.0	115
40	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. Lung Cancer, 2019, 134, 167-173.	2.0	9
41	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Journal of Clinical Oncology, 2019, 37, 2738-2745.	1.6	138
42	Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors. Mediastinum, 2019, 3, 3-3.	1.1	0
43	P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIb NSCLC: Update on LCMC3 Clinical Trial. Journal of Thoracic Oncology, 2019, 14, S744.	1.1	7
44	MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. Journal of Thoracic Oncology, 2019, 14, S294-S295.	1.1	3
45	EP1.12-38 Retrospective Analysis of Immunotherapy Utilization in Advanced Small Cell Carcinoma at an Academic Cancer Center. Journal of Thoracic Oncology, 2019, 14, S1030.	1.1	0
46	OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3. Journal of Thoracic Oncology, 2019, 14, S242-S243.	1.1	6
47	P1.01-71 Bone Metastases and Skeletal-Related Events in Patients with Metastatic NSCLC Treated with ICIs: A Multi-Institutional Study. Journal of Thoracic Oncology, 2019, 14, S387.	1.1	1
48	775 Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. American Journal of Gastroenterology, 2019, 114, S450-S451.	0.4	1
49	Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.. Journal of Clinical Oncology, 2019, 37, 2577-2577.	1.6	2
50	Is immunotherapy toxicity associated with improved overall survival among older adults with advanced cancer?. Journal of Clinical Oncology, 2019, 37, 6580-6580.	1.6	1
51	Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration.. Journal of Clinical Oncology, 2019, 37, 118-118.	1.6	1
52	Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy.. Journal of Clinical Oncology, 2019, 37, 94-94.	1.6	4
53	KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 409-413.	4.9	30
54	Recurrent and de-novo autoimmune hemolytic anemia in patients treated with immunotherapy for advanced cancer.. Journal of Clinical Oncology, 2019, 37, e14170-e14170.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Re-evaluating the neutrophil-to-lymphocyte ratio: Machine learning-based variable selection for predicting survival at twelve months in late-stage cancer patients receiving immunotherapy.. Journal of Clinical Oncology, 2019, 37, e18201-e18201.	1.6	0
56	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 50-58.	4.9	41
57	Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. Journal of Thoracic Oncology, 2018, 13, 1204-1212.	1.1	46
58	Immunotherapy in surgically resectable non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S404-S411.	1.4	53
59	Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?. Journal of Thoracic Disease, 2018, 10, S4069-S4072.	1.4	3
60	End of life resource utilization among patients receiving immunotherapy for advanced cancer. Annals of Oncology, 2018, 29, viii553.	1.2	1
61	Immune related adverse events across cancer types: Incidence, risk factors and survival. Annals of Oncology, 2018, 29, viii630-viii631.	1.2	4
62	MA04.10 Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC. Journal of Thoracic Oncology, 2018, 13, S369.	1.1	1
63	Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. Journal of Thoracic Oncology, 2018, 13, 1595-1601.	1.1	137
64	Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1035-1040.	4.9	24
65	Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e893-e900.	2.6	98
66	Multicenter phase 2 study of nintedanib in patients (pts) with advanced progressing carcinoid tumors.. Journal of Clinical Oncology, 2018, 36, 4105-4105.	1.6	5
67	P2.04-020 Expression Patterns and Prognostic Value of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. Journal of Thoracic Oncology, 2017, 12, S1008-S1009.	1.1	2
68	P2.06-019 A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S1082.	1.1	0
69	MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers. Journal of Thoracic Oncology, 2017, 12, S435-S436.	1.1	1
70	Systemic Therapy for Advanced Metastatic Thyroid Cancer. , 2017, , 433-450.		0
71	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of Clinical Oncology, 2017, 35, 1403-1410.	1.6	277
72	Favorable and Durable Response to Pazopanib in Metastatic Refractory Paraganglioma. Journal of Oncology Practice, 2017, 13, 840-842.	2.5	4

#	ARTICLE	IF	CITATIONS
73	New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases. <i>Journal of Thoracic Disease</i> , 2017, 9, E158-E161.	1.4	0
74	Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9080-9080.	1.6	12
75	A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8580-TPS8580.	1.6	2
76	Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response. <i>Oncotarget</i> , 2017, 8, 104046-104056.	1.8	35
77	Outcomes of metastatic adrenocortical carcinoma (ACC): A 16-year single institutional experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16088-e16088.	1.6	0
78	Targeting RET in patients with <i>RET</i> -rearranged lung cancers: Results from a global registry.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9014-9014.	1.6	8
79	Abstract 3116: MGMT immunohistochemistry (IHC) as a biomarker for response to combination therapy with capecitabine and temozolomide (C/T) in patients (pts) with advanced neuroendocrine carcinomas (aNEC). , 2016, , .		0
80	An Early Lesson. <i>Journal of Palliative Medicine</i> , 2015, 18, 86-86.	1.1	0
81	Hepatocellular carcinoma (HCC) and bone metastases (Mets).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15129-e15129.	1.6	1
82	ASSOCIATION OF TRANSFORMING GROWTH FACTOR- β 1 GENE POLYMORPHISM WITH REFLUX NEPHROPATHY. <i>Journal of Urology</i> , 2005, 174, 1609-1611.	0.4	40